Computational Biology - Market Insights, Competitive Landscape, and Market Forecast - 2034
Description
Computational Biology Market Summary
Overview
Computational Biology Market Key Growth Drivers
The leading participants in the computational biology market include the following:
Market Drivers
Rapid Expansion of Multi-Omics Research
The foundational driver of the computational biology market is the rapid expansion of multi-omics research integrating genomics, transcriptomics, proteomics, and metabolomics data into unified biological analyses. As research programs increasingly seek to understand biological systems holistically rather than through single-omics analysis alone, the computational demands of integrating, normalizing, and jointly analyzing these large, multidimensional, and heterogeneous datasets grow substantially. As multi-omics research continues to expand across academic and pharmaceutical research settings, demand for computational biology platforms capable of handling this analytical complexity grows correspondingly across the forecast period.
Increasing Integration of Artificial Intelligence and Machine Learning
The increasing integration of artificial intelligence and machine learning into biological data analysis is fundamentally reshaping the computational biology market's technology base. In May 2026, QIAGEN enhanced its bioinformatics portfolio by integrating NVIDIA-accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights, improving AI-enabled analysis of biological data and accelerating drug discovery workflows, while BGI Genomics unveiled its SIROmics AI-enabled bioinformatics solution in March 2026 to support high-throughput genetic testing through combined laboratory automation and advanced data analysis. As AI and machine learning capabilities continue to be integrated across computational biology platforms, the speed, accuracy, and analytical depth achievable in genomic interpretation, drug target identification, and biomarker discovery continue to improve, driving adoption across the forecast period.
Market Restraints
The computational biology market faces several interrelated restraints that temper its growth. The high cost of advanced computational biology software licenses, cloud computing infrastructure, and specialized high-performance computing resources constrains adoption among smaller academic laboratories and organizations operating with limited research budgets. The requirement for specialized computational biology, bioinformatics, and data science expertise to effectively operate advanced platforms and interpret complex biological datasets limits adoption where this specialized talent is in short supply. Data privacy and security concerns associated with handling sensitive genomic and clinical data, particularly across cloud-based platforms, require rigorous compliance with data protection regulations that add cost and complexity to computational biology platform deployment. The complexity of validating and standardizing computational predictions against experimental biological reality remains an ongoing technical challenge, as computational models do not always accurately predict real-world biological behavior, requiring continued experimental validation. Interoperability challenges between different computational biology platforms, data formats, and analytical pipelines can complicate multi-platform workflows and limit the ease of integrating computational biology tools across an organization's broader research technology stack. Together, these factors moderate the pace of adoption and require vendors to demonstrate validated predictive accuracy, ease of use, and total cost of ownership advantages to sustain growth.
Computational Biology Market Segment Analysis
The global computational biology market is segmented by offering (software/platforms and services), by application (bioinformatics and sequence analytics, molecular modeling and simulation, AI-driven drug discovery platforms, systems biology, multi-omics data integration, and clinical trial simulation), by deployment mode (cloud-based and on-premise), by end-user (pharmaceutical and biotechnology companies, academic and research institutes, contract research and development organizations, and hospitals and diagnostic laboratories), and by geography (North America, Europe, Asia-Pacific, and the Rest of the World).
By Offering
Dominant Subsegment: Software/Platforms.
The software/platforms category is expected to dominate the market. Software and platforms, including bioinformatics platforms, molecular modeling tools, omics analysis software, and translational data systems from QIAGEN, Schrödinger, and Dassault Systèmes' BIOVIA business, are the leading offering because they perform the core function underlying standard computational biology processes and because most end users depend on licensed or subscription software to handle biological data, conduct analyses, model molecular interactions, and support discovery and precision medicine initiatives. The dominance of the segment reflects the scalable, recurring-revenue nature of software licensing and subscription models, which customers frequently expand through cloud deployment, hosted environments, and additional analytics modules over time, as reflected in Schrödinger's reported 2025 software revenue growth. Services, including data analysis, consulting, and custom bioinformatics pipeline development, represent a substantial complementary category supporting organizations that lack in-house computational biology expertise.
By Application
Dominant Subsegment: Bioinformatics and Sequence Analytics.
The bioinformatics and sequence analytics category is expected to dominate the market. Bioinformatics and sequence analytics is the leading application because most computational biology workflows begin with sequencing data generation, followed by read processing, alignment, variant interpretation, and expression analysis, making this application foundational to nearly every downstream computational biology use case. The dominance of the segment reflects the universal role sequence analysis plays across genomics research, clinical diagnostics, and precision medicine applications. AI-driven drug discovery platforms represented the fastest-growing application, driven by accelerating adoption of generative AI tools for molecule design that improve prediction accuracy and shorten drug discovery timelines, while molecular modeling and simulation, systems biology, multi-omics data integration, and clinical trial simulation remain substantial and growing application categories.
Computational Biology Market Region Analysis
Dominant Region: North America
North America accounted for a 50% share of the global computational biology market in 2025, representing the highest regional market share globally. The leadership of the region reflects the concentration of leading computational biology software providers, substantial pharmaceutical and biotechnology research and development investment, and advanced genomics research infrastructure. The United States is the largest national market, supported by the concentration of leading companies including Schrödinger and DNAnexus, sustained National Institutes of Health research funding, and an active biopharmaceutical drug discovery pipeline increasingly reliant on computational approaches. The concentration of vendors, research investment, and genomics infrastructure reinforce the position of North America as the largest regional market across the forecast period.
Fastest Growing Region: Asia-Pacific
Asia-Pacific is projected to register the fastest compound annual growth rate through 2034. The region is expanding genomics research infrastructure and biopharmaceutical research capacity, supported by growing government investment in precision medicine and genomics research programs. China, Japan, and India are the principal national markets, supported by expanding academic and biotechnology research capacity, government investment in genomics infrastructure, and the growing presence of domestic computational biology and bioinformatics companies such as BGI Genomics. As genomics research infrastructure continues to expand and as government investment in precision medicine research grows, Asia-Pacific is positioned as the fastest-growing regional market across the forecast period.
Regional Commentary
North America
North America leads the market, supported by the concentration of leading computational biology software providers and substantial pharmaceutical research investment. The United States dominates the region through its concentration of companies and sustained research funding.
Europe
Europe is a substantial market shaped by strong academic genomics research infrastructure and the presence of leading companies including QIAGEN, Genedata, and Dassault Systèmes. Germany, the United Kingdom, France, Italy, and Spain are the principal national markets, and the region continues to advance AI-powered drug discovery platforms through companies such as Genedata.
Asia-Pacific
Asia-Pacific is the fastest-growing region, driven by expanding genomics research infrastructure and growing government investment in precision medicine research across China, Japan, and India.
Rest of World
The Rest of World, spanning Latin America, the Middle East, and Africa, represents an emerging opportunity as genomics and computational biology research infrastructure expands, though adoption remains concentrated in leading academic and private research centers, with Canada notably supported by sustained Genome Canada funding for translational genomics research.
Computational Biology Market Competitive Landscape
The global computational biology market is classified as Moderately Consolidated. A group of established life science and software companies, including QIAGEN, Illumina, and Thermo Fisher Scientific, holds a substantial share of the market through comprehensive bioinformatics and genomics software portfolios, while specialist companies, including Schrödinger in molecular modeling and Insilico Medicine and Genedata in AI-driven drug discovery, compete on differentiated computational platforms. Competition centers on breadth of the computational biology software portfolio, depth of AI and machine learning integration, cloud deployment capability, and validated predictive accuracy across drug discovery and genomic interpretation applications. The competitive landscape is evaluated across the following dimensions:
Computational Biology Market Assessment by Offering
Canada Computational Biology Market Size in USD million (2023-2034)
Mexico Computational Biology Market Size in USD million (2023-2034)
United Kingdom Computational Biology Market Size in USD million (2023-2034)
France Computational Biology Market Size in USD million (2023-2034)
Italy Computational Biology Market Size in USD million (2023-2034)
Spain Computational Biology Market Size in USD million (2023-2034)
Rest of Europe Computational Biology Market Size in USD million (2023-2034)
Japan Computational Biology Market Size in USD million (2023-2034)
India Computational Biology Market Size in USD million (2023-2034)
Australia Computational Biology Market Size in USD million (2023-2034)
South Korea Computational Biology Market Size in USD million (2023-2034)
Rest of Asia-Pacific Computational Biology Market Size in USD million (2023-2034)
Africa Computational Biology Market Size in USD million (2023-2034)
South America Computational Biology Market Size in USD million (2023-2034)
Key Takeaways from the Computational Biology Market Report Study
Q1. At what rate is the computational biology market expected to grow?
The global computational biology market is projected to grow at a compound annual growth rate of 14.0% during the forecast period from 2026 to 2034.
Q2. What is the current and projected size of the computational biology market?
The global computational biology market was valued at USD 9.2 billion in 2025 and is projected to reach USD 26.8 billion by 2034.
Q3. Which region dominates the computational biology market?
North America dominated the computational biology market with a 50% share in 2025, driven by the concentration of leading software providers and substantial pharmaceutical research investment. Asia-Pacific is projected to record the fastest compound annual growth rate through 2034, driven by expanding genomics research infrastructure across China, Japan, and India.
Q4. What are the key factors driving growth in the computational biology market?
The principal drivers are the rapid expansion of multi-omics research; increasing integration of artificial intelligence and machine learning into biological data analysis; rising demand for precision medicine; the growing volume of next-generation sequencing data; and accelerating adoption of generative AI tools for drug discovery.
Q5. Who are the major players in the computational biology market?
The market is moderately consolidated and led by QIAGEN N.V., Illumina, Inc., and Thermo Fisher Scientific Inc., alongside Schrödinger, Inc., Genedata AG, Dassault Systèmes SE, DNAnexus, Inc., Seven Bridges Genomics, Benchling, Inc., and Insilico Medicine.
Overview
- The global computational biology market was valued at USD 9.2 billion in 2025 and is projected to reach USD 26.8 billion by 2034.
- The market is expected to expand at a CAGR of 14.0% during the forecast period 2026-2034, supported by the rapid expansion of multi-omics research, increasing integration of artificial intelligence and machine learning into biological data analysis, rising demand for precision medicine, and the growing volume of genomic data generated by next-generation sequencing platforms.
- By offering, the software/platforms segment dominated the computational biology market in 2025.
- By application, bioinformatics and sequence analytics dominated the computational biology market in 2025, while AI-driven drug discovery platforms represented the fastest-growing application.
- By deployment mode, cloud-based platforms dominated the computational biology market in 2025.
- By end-user, pharmaceutical and biotechnology companies dominated the computational biology market with a 55% share in 2025, while contract research and development organizations represented the fastest-growing end-user.
- North America accounted for the largest share of the computational biology market at 50% in 2025, while Asia-Pacific is anticipated to register the fastest growth through 2034.
Computational Biology Market Key Growth Drivers
- Rapid expansion of multi-omics research integrating genomics, transcriptomics, proteomics, and metabolomics data, requiring increasingly sophisticated computational platforms to analyze and interpret these large, multidimensional datasets.
- Increasing integration of artificial intelligence and machine learning into biological data analysis, exemplified by QIAGEN's May 2026 integration of NVIDIA-accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights.
- Rising demand for precision medicine, which depends on computational analysis of individual patient genomic, molecular, and clinical data to guide diagnosis and treatment selection.
- Growing volume of genomic data generated by next-generation sequencing platforms, creating sustained demand for the bioinformatics and sequence analytics software required to process, align, and interpret this data at scale.
- Accelerating adoption of generative AI tools for molecule design and drug discovery, which improve prediction accuracy and significantly shorten drug discovery timelines relative to traditional experimental approaches.
- Increasing pharmaceutical industry demand for computational tools that simulate biological processes, identify drug targets, and reduce dependency on time-consuming laboratory experimentation.
- Sustained government investment in genomics research infrastructure, exemplified by Genome Canada's ongoing funding commitment exceeding USD 1.6 billion over more than 20 years for large-scale applied and translational genomics.
The leading participants in the computational biology market include the following:
- QIAGEN N.V.
- Illumina, Inc.
- Thermo Fisher Scientific Inc.
- Schrödinger, Inc.
- Genedata AG
- Dassault Systèmes SE (BIOVIA)
- DNAnexus, Inc.
- Seven Bridges Genomics (Velsera)
- Benchling, Inc.
- Insilico Medicine
Market Drivers
Rapid Expansion of Multi-Omics Research
The foundational driver of the computational biology market is the rapid expansion of multi-omics research integrating genomics, transcriptomics, proteomics, and metabolomics data into unified biological analyses. As research programs increasingly seek to understand biological systems holistically rather than through single-omics analysis alone, the computational demands of integrating, normalizing, and jointly analyzing these large, multidimensional, and heterogeneous datasets grow substantially. As multi-omics research continues to expand across academic and pharmaceutical research settings, demand for computational biology platforms capable of handling this analytical complexity grows correspondingly across the forecast period.
Increasing Integration of Artificial Intelligence and Machine Learning
The increasing integration of artificial intelligence and machine learning into biological data analysis is fundamentally reshaping the computational biology market's technology base. In May 2026, QIAGEN enhanced its bioinformatics portfolio by integrating NVIDIA-accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights, improving AI-enabled analysis of biological data and accelerating drug discovery workflows, while BGI Genomics unveiled its SIROmics AI-enabled bioinformatics solution in March 2026 to support high-throughput genetic testing through combined laboratory automation and advanced data analysis. As AI and machine learning capabilities continue to be integrated across computational biology platforms, the speed, accuracy, and analytical depth achievable in genomic interpretation, drug target identification, and biomarker discovery continue to improve, driving adoption across the forecast period.
Market Restraints
The computational biology market faces several interrelated restraints that temper its growth. The high cost of advanced computational biology software licenses, cloud computing infrastructure, and specialized high-performance computing resources constrains adoption among smaller academic laboratories and organizations operating with limited research budgets. The requirement for specialized computational biology, bioinformatics, and data science expertise to effectively operate advanced platforms and interpret complex biological datasets limits adoption where this specialized talent is in short supply. Data privacy and security concerns associated with handling sensitive genomic and clinical data, particularly across cloud-based platforms, require rigorous compliance with data protection regulations that add cost and complexity to computational biology platform deployment. The complexity of validating and standardizing computational predictions against experimental biological reality remains an ongoing technical challenge, as computational models do not always accurately predict real-world biological behavior, requiring continued experimental validation. Interoperability challenges between different computational biology platforms, data formats, and analytical pipelines can complicate multi-platform workflows and limit the ease of integrating computational biology tools across an organization's broader research technology stack. Together, these factors moderate the pace of adoption and require vendors to demonstrate validated predictive accuracy, ease of use, and total cost of ownership advantages to sustain growth.
Computational Biology Market Segment Analysis
The global computational biology market is segmented by offering (software/platforms and services), by application (bioinformatics and sequence analytics, molecular modeling and simulation, AI-driven drug discovery platforms, systems biology, multi-omics data integration, and clinical trial simulation), by deployment mode (cloud-based and on-premise), by end-user (pharmaceutical and biotechnology companies, academic and research institutes, contract research and development organizations, and hospitals and diagnostic laboratories), and by geography (North America, Europe, Asia-Pacific, and the Rest of the World).
By Offering
Dominant Subsegment: Software/Platforms.
The software/platforms category is expected to dominate the market. Software and platforms, including bioinformatics platforms, molecular modeling tools, omics analysis software, and translational data systems from QIAGEN, Schrödinger, and Dassault Systèmes' BIOVIA business, are the leading offering because they perform the core function underlying standard computational biology processes and because most end users depend on licensed or subscription software to handle biological data, conduct analyses, model molecular interactions, and support discovery and precision medicine initiatives. The dominance of the segment reflects the scalable, recurring-revenue nature of software licensing and subscription models, which customers frequently expand through cloud deployment, hosted environments, and additional analytics modules over time, as reflected in Schrödinger's reported 2025 software revenue growth. Services, including data analysis, consulting, and custom bioinformatics pipeline development, represent a substantial complementary category supporting organizations that lack in-house computational biology expertise.
By Application
Dominant Subsegment: Bioinformatics and Sequence Analytics.
The bioinformatics and sequence analytics category is expected to dominate the market. Bioinformatics and sequence analytics is the leading application because most computational biology workflows begin with sequencing data generation, followed by read processing, alignment, variant interpretation, and expression analysis, making this application foundational to nearly every downstream computational biology use case. The dominance of the segment reflects the universal role sequence analysis plays across genomics research, clinical diagnostics, and precision medicine applications. AI-driven drug discovery platforms represented the fastest-growing application, driven by accelerating adoption of generative AI tools for molecule design that improve prediction accuracy and shorten drug discovery timelines, while molecular modeling and simulation, systems biology, multi-omics data integration, and clinical trial simulation remain substantial and growing application categories.
Computational Biology Market Region Analysis
Dominant Region: North America
North America accounted for a 50% share of the global computational biology market in 2025, representing the highest regional market share globally. The leadership of the region reflects the concentration of leading computational biology software providers, substantial pharmaceutical and biotechnology research and development investment, and advanced genomics research infrastructure. The United States is the largest national market, supported by the concentration of leading companies including Schrödinger and DNAnexus, sustained National Institutes of Health research funding, and an active biopharmaceutical drug discovery pipeline increasingly reliant on computational approaches. The concentration of vendors, research investment, and genomics infrastructure reinforce the position of North America as the largest regional market across the forecast period.
Fastest Growing Region: Asia-Pacific
Asia-Pacific is projected to register the fastest compound annual growth rate through 2034. The region is expanding genomics research infrastructure and biopharmaceutical research capacity, supported by growing government investment in precision medicine and genomics research programs. China, Japan, and India are the principal national markets, supported by expanding academic and biotechnology research capacity, government investment in genomics infrastructure, and the growing presence of domestic computational biology and bioinformatics companies such as BGI Genomics. As genomics research infrastructure continues to expand and as government investment in precision medicine research grows, Asia-Pacific is positioned as the fastest-growing regional market across the forecast period.
Regional Commentary
North America
North America leads the market, supported by the concentration of leading computational biology software providers and substantial pharmaceutical research investment. The United States dominates the region through its concentration of companies and sustained research funding.
Europe
Europe is a substantial market shaped by strong academic genomics research infrastructure and the presence of leading companies including QIAGEN, Genedata, and Dassault Systèmes. Germany, the United Kingdom, France, Italy, and Spain are the principal national markets, and the region continues to advance AI-powered drug discovery platforms through companies such as Genedata.
Asia-Pacific
Asia-Pacific is the fastest-growing region, driven by expanding genomics research infrastructure and growing government investment in precision medicine research across China, Japan, and India.
Rest of World
The Rest of World, spanning Latin America, the Middle East, and Africa, represents an emerging opportunity as genomics and computational biology research infrastructure expands, though adoption remains concentrated in leading academic and private research centers, with Canada notably supported by sustained Genome Canada funding for translational genomics research.
Computational Biology Market Competitive Landscape
The global computational biology market is classified as Moderately Consolidated. A group of established life science and software companies, including QIAGEN, Illumina, and Thermo Fisher Scientific, holds a substantial share of the market through comprehensive bioinformatics and genomics software portfolios, while specialist companies, including Schrödinger in molecular modeling and Insilico Medicine and Genedata in AI-driven drug discovery, compete on differentiated computational platforms. Competition centers on breadth of the computational biology software portfolio, depth of AI and machine learning integration, cloud deployment capability, and validated predictive accuracy across drug discovery and genomic interpretation applications. The competitive landscape is evaluated across the following dimensions:
- Market concentration: Moderately consolidated, with QIAGEN, Illumina, and Thermo Fisher Scientific holding a substantial share, alongside Schrödinger, Genedata, Dassault Systèmes, DNAnexus, Seven Bridges Genomics, Benchling, and Insilico Medicine.
- Leading players: QIAGEN leads in bioinformatics platforms through QIAGEN Digital Insights, reinforced by its 2026 NVIDIA BioNeMo integration; Schrödinger leads in molecular modeling and simulation software; and Insilico Medicine and Genedata lead in AI-driven drug discovery platform development.
- Geographic reach: QIAGEN, Illumina, and Thermo Fisher Scientific operate global commercial organizations, while specialist companies including Genedata and Dassault Systèmes maintain strong footprints concentrated in Europe, and DNAnexus and Schrödinger maintain concentrated but expanding operations centered on North America.
- Product portfolio strength: Competitive advantage rests on the breadth across bioinformatics, molecular modeling, AI-driven drug discovery, and cloud genomics platforms, and on the depth of AI and machine learning integration across these categories.
- Pipeline strength: Development is concentrated in generative AI-driven drug discovery platforms, AI-accelerated genomic interpretation, and expanded multi-omics data integration capability.
- Strategic partnerships: Collaboration spans AI infrastructure partnerships, exemplified by QIAGEN's 2026 integration of NVIDIA-accelerated computing and the BioNeMo platform, and platform expansion partnerships supporting cloud-based genomics and drug discovery workflows.
- M&A activity: Consolidation has shaped the field, with strategic partnerships and platform integration activity, including AI infrastructure collaborations and cloud genomics platform expansion, occurring more frequently than large-scale acquisitions in the current market environment.
- Innovation focus: Innovation is concentrated in generative AI-driven molecule design and drug discovery, AI-accelerated bioinformatics and genomic interpretation, and cloud-based platforms supporting collaborative, scalable computational biology workflows.
- Regulatory standing: Compliance with data privacy and security regulations governing genomic and clinical data, and alignment with FDA and other regulatory body standards for computational tools used in healthcare and drug discovery applications, are decisive competitive credentials across this market.
- In May 2026, QIAGEN enhanced its bioinformatics portfolio by integrating NVIDIA-accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights, improving AI-enabled analysis of biological data and accelerating drug discovery workflows. Strategic significance: the integration positioned QIAGEN at the forefront of AI-accelerated computational biology infrastructure.
- In March 2026, BGI Genomics unveiled SIROmics, an AI-enabled bioinformatics solution designed to support high-throughput genetic testing by combining laboratory automation with advanced data analysis and reporting. Strategic significance: the launch reinforced BGI Genomics' position in AI-enabled genomic testing infrastructure.
Computational Biology Market Assessment by Offering
- Software/Platforms
- Services
- Bioinformatics and Sequence Analytics
- Molecular Modeling and Simulation
- AI-Driven Drug Discovery Platforms
- Systems Biology
- Multi-Omics Data Integration
- Clinical Trial Simulation
- Cloud-Based
- On-Premise
- Pharmaceutical and Biotechnology Companies
- Academic and Research Institutes
- Contract Research and Development Organizations
- Hospitals and Diagnostic Laboratories
- North America
Canada Computational Biology Market Size in USD million (2023-2034)
Mexico Computational Biology Market Size in USD million (2023-2034)
- Europe
United Kingdom Computational Biology Market Size in USD million (2023-2034)
France Computational Biology Market Size in USD million (2023-2034)
Italy Computational Biology Market Size in USD million (2023-2034)
Spain Computational Biology Market Size in USD million (2023-2034)
Rest of Europe Computational Biology Market Size in USD million (2023-2034)
- Asia-Pacific
Japan Computational Biology Market Size in USD million (2023-2034)
India Computational Biology Market Size in USD million (2023-2034)
Australia Computational Biology Market Size in USD million (2023-2034)
South Korea Computational Biology Market Size in USD million (2023-2034)
Rest of Asia-Pacific Computational Biology Market Size in USD million (2023-2034)
- Rest of the World
Africa Computational Biology Market Size in USD million (2023-2034)
South America Computational Biology Market Size in USD million (2023-2034)
Key Takeaways from the Computational Biology Market Report Study
- Market size analysis for the current computational biology market size (2025), and market forecast for 9 years (2026 to 2034).
- Top key product and technology developments, partnerships, and platform integrations that have happened over the last 3 years.
- Key companies dominating the global computational biology market.
- Various opportunities available for competitors in the computational biology market space.
- What are the top-performing segments in 2025? How will these segments perform in 2034?
- Which are the top-performing regions and countries in the current computational biology market scenario?
- Which are the regions and countries where companies should concentrate their opportunities for computational biology market growth in the future?
- Computational biology and bioinformatics software providers
- Research organizations and consulting companies
- Genomics and precision medicine-related organizations, associations, forums, and other alliances
- Government and corporate offices
- Start-up companies, venture capitalists, and private equity firms
- Distributors and partners dealing in computational biology software and platforms
- Various end-users who want to know more about the computational biology market and the latest technological developments in the computational biology market.
Q1. At what rate is the computational biology market expected to grow?
The global computational biology market is projected to grow at a compound annual growth rate of 14.0% during the forecast period from 2026 to 2034.
Q2. What is the current and projected size of the computational biology market?
The global computational biology market was valued at USD 9.2 billion in 2025 and is projected to reach USD 26.8 billion by 2034.
Q3. Which region dominates the computational biology market?
North America dominated the computational biology market with a 50% share in 2025, driven by the concentration of leading software providers and substantial pharmaceutical research investment. Asia-Pacific is projected to record the fastest compound annual growth rate through 2034, driven by expanding genomics research infrastructure across China, Japan, and India.
Q4. What are the key factors driving growth in the computational biology market?
The principal drivers are the rapid expansion of multi-omics research; increasing integration of artificial intelligence and machine learning into biological data analysis; rising demand for precision medicine; the growing volume of next-generation sequencing data; and accelerating adoption of generative AI tools for drug discovery.
Q5. Who are the major players in the computational biology market?
The market is moderately consolidated and led by QIAGEN N.V., Illumina, Inc., and Thermo Fisher Scientific Inc., alongside Schrödinger, Inc., Genedata AG, Dassault Systèmes SE, DNAnexus, Inc., Seven Bridges Genomics, Benchling, Inc., and Insilico Medicine.
Table of Contents
150 Pages
- 1. Computational Biology Market Introduction
- 1.1. Scope of the Report
- 1.2. Market Segmentation
- 1.3. Market Overview at a Glance
- 2. Computational Biology Market Executive Summary
- 2.1. Key Highlights and Market Snapshot
- 3. Computational Biology Market Key Factors Analysis
- 3.1. Market Drivers
- 3.1.1. Rapid Expansion of Multi-Omics Research
- 3.1.2. Increasing Integration of Artificial Intelligence and Machine Learning
- 3.1.3. Rising Demand for Precision Medicine
- 3.1.4. Growing Volume of Next-Generation Sequencing Data
- 3.2. Market Restraints
- 3.2.1. High Cost of Software and Computing Infrastructure
- 3.2.2. Requirement for Specialized Computational Expertise
- 3.2.3. Data Privacy and Security Concerns
- 3.3. Market Opportunities
- 3.3.1. Generative AI-Driven Drug Discovery
- 3.3.2. AI-Accelerated Genomic Interpretation Infrastructure
- 4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments
- 5. Regulatory Analysis
- 5.1. The United States
- 5.2. Europe
- 5.3. Japan
- 5.4. China
- 6. Computational Biology Market Porter's Five Forces Analysis
- 6.1. Bargaining Power of Suppliers
- 6.2. Bargaining Power of Consumers
- 6.3. Threat of New Entrants
- 6.4. Threat of Substitutes
- 6.5. Competitive Rivalry
- 7. Computational Biology Market Assessment
- 7.1. By Offering
- 7.1.1. Software/Platforms
- 7.1.2. Services
- 7.2. By Application
- 7.2.1. Bioinformatics and Sequence Analytics
- 7.2.2. Molecular Modeling and Simulation
- 7.2.3. AI-Driven Drug Discovery Platforms
- 7.2.4. Systems Biology
- 7.2.5. Multi-Omics Data Integration
- 7.2.6. Clinical Trial Simulation
- 7.3. By Deployment Mode
- 7.3.1. Cloud-Based
- 7.3.2. On-Premise
- 7.4. By End-User
- 7.4.1. Pharmaceutical and Biotechnology Companies
- 7.4.2. Academic and Research Institutes
- 7.4.3. Contract Research and Development Organizations
- 7.4.4. Hospitals and Diagnostic Laboratories
- 7.5. By Geography
- 7.5.1. North America
- 7.5.1.1. United States Computational Biology Market Size in USD million (2023-2034)
- 7.5.1.2. Canada Computational Biology Market Size in USD million (2023-2034)
- 7.5.1.3. Mexico Computational Biology Market Size in USD million (2023-2034)
- 7.5.2. Europe
- 7.5.2.1. Germany Computational Biology Market Size in USD million (2023-2034)
- 7.5.2.2. United Kingdom Computational Biology Market Size in USD million (2023-2034)
- 7.5.2.3. France Computational Biology Market Size in USD million (2023-2034)
- 7.5.2.4. Italy Computational Biology Market Size in USD million (2023-2034)
- 7.5.2.5. Spain Computational Biology Market Size in USD million (2023-2034)
- 7.5.2.6. Rest of Europe Computational Biology Market Size in USD million (2023-2034)
- 7.5.3. Asia-Pacific
- 7.5.3.1. China Computational Biology Market Size in USD million (2023-2034)
- 7.5.3.2. Japan Computational Biology Market Size in USD million (2023-2034)
- 7.5.3.3. India Computational Biology Market Size in USD million (2023-2034)
- 7.5.3.4. Australia Computational Biology Market Size in USD million (2023-2034)
- 7.5.3.5. South Korea Computational Biology Market Size in USD million (2023-2034)
- 7.5.3.6. Rest of Asia-Pacific Computational Biology Market Size in USD million (2023-2034)
- 7.5.4. Rest of the World
- 7.5.4.1. Middle East Computational Biology Market Size in USD million (2023-2034)
- 7.5.4.2. Africa Computational Biology Market Size in USD million (2023-2034)
- 7.5.4.3. South America Computational Biology Market Size in USD million (2023-2034)
- 8. Computational Biology Market Competitive Landscape
- 8.1. Competitive Analysis
- 8.2. Company Share Analysis (Premium Offering)
- 9. Computational Biology Market Startup Funding and Investment Trends
- 10. Computational Biology Market Company and Product Profiles
- 10.1. QIAGEN N.V.
- 10.1.1. Company Overview
- 10.1.2. Company Snapshot
- 10.1.3. Financial Overview
- 10.1.4. Product/Platform Portfolio
- 10.1.5. Entropy
- 10.2. Illumina, Inc.
- 10.2.1. Company Overview
- 10.2.2. Company Snapshot
- 10.2.3. Financial Overview
- 10.2.4. Product/Platform Portfolio
- 10.2.5. Entropy
- 10.3. Thermo Fisher Scientific Inc.
- 10.3.1. Company Overview
- 10.3.2. Company Snapshot
- 10.3.3. Financial Overview
- 10.3.4. Product/Platform Portfolio
- 10.3.5. Entropy
- 10.4. Schrödinger, Inc.
- 10.4.1. Company Overview
- 10.4.2. Company Snapshot
- 10.4.3. Financial Overview
- 10.4.4. Product/Platform Portfolio
- 10.4.5. Entropy
- 10.5. Genedata AG
- 10.5.1. Company Overview
- 10.5.2. Company Snapshot
- 10.5.3. Financial Overview
- 10.5.4. Product/Platform Portfolio
- 10.5.5. Entropy
- 10.6. Dassault Systèmes SE (BIOVIA)
- 10.6.1. Company Overview
- 10.6.2. Company Snapshot
- 10.6.3. Financial Overview
- 10.6.4. Product/Platform Portfolio
- 10.6.5. Entropy
- 10.7. DNAnexus, Inc.
- 10.7.1. Company Overview
- 10.7.2. Company Snapshot
- 10.7.3. Financial Overview
- 10.7.4. Product/Platform Portfolio
- 10.7.5. Entropy
- 10.8. Seven Bridges Genomics (Velsera)
- 10.8.1. Company Overview
- 10.8.2. Company Snapshot
- 10.8.3. Financial Overview
- 10.8.4. Product/Platform Portfolio
- 10.8.5. Entropy
- 10.9. Benchling, Inc.
- 10.9.1. Company Overview
- 10.9.2. Company Snapshot
- 10.9.3. Financial Overview
- 10.9.4. Product/Platform Portfolio
- 10.9.5. Entropy
- 10.10. Insilico Medicine
- 10.10.1. Company Overview
- 10.10.2. Company Snapshot
- 10.10.3. Financial Overview
- 10.10.4. Product/Platform Portfolio
- 10.10.5. Entropy
- For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.
- 11. KOL Views
- 12. Project Approach
- 13. About DelveInsight
- 14. Disclaimer and Contact Us
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
